VRDNMEDIUM SIGNALFINANCIAL10-K

VRDN shows a substantial increase in shares outstanding alongside significantly higher operating losses and declining cash position, indicating continued capital dilution and cash burn acceleration.

The 25% increase in shares outstanding (from 81.5M to 102.2M shares) signals meaningful dilution to existing shareholders as the company raised capital. Combined with substantially higher operating losses and declining cash reserves, this suggests VRDN is consuming capital at an accelerated pace while advancing its clinical programs.

Comparing 2026-02-26 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

The company's financial position reflects typical biotech capital consumption patterns, with current assets growing 21% to $894M likely from equity raises, while cash declined 31% to $32.6M indicating ongoing operational burn. Operating losses expanded meaningfully as SG&A expenses grew substantially while R&D spending increased more modestly by 14%, suggesting increased infrastructure investment alongside continued clinical development activities. The overall picture shows a biotech company actively funding operations through equity dilution while burning cash at an accelerated rate.

FINANCIAL STATEMENT CHANGES
Inventory
Balance Sheet
-65.8%
$187K→$64K

Inventory drawn down 65.8% — strong sell-through or deliberate destocking; watch for supply constraints.

SG&A Expense
P&L
+56%
$61.1M→$95.3M

SG&A up 56% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Current Liabilities
Balance Sheet
+47.7%
$47.9M→$70.7M

Current liabilities surged 47.7% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
-31.3%
$47.4M→$32.6M

Cash declined 31.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Net Income
P&L
-26.9%
-$269.9M→-$342.6M

Net income declined 26.9% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-21.5%
-$299.0M→-$363.4M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Total Assets
Balance Sheet
+21.1%
$742.4M→$899.4M

Asset base grew 21.1% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+21.1%
$738.5M→$894.2M

Current assets grew 21.1% — improving short-term liquidity or inventory/receivables build.

Operating Cash Flow
Cash Flow
-19%
-$232.3M→-$276.4M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

R&D Expense
P&L
+14.4%
$30.4M→$34.8M

R&D investment increased 14.4% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-03
ADDED
As of February 20, 2026, there were 102,206,571 shares of the registrant s common stock outstanding.
Any of our product candidates may fail in development or experience significant delays.
Regulatory approval processes are lengthy, time-consuming and inherently unpredictable, and we may be unable to obtain approval for our product candidates or approval may be delayed due to factors beyond our control, including as a result of disruptions at the FDA and other agencies caused by shutdowns, funding shortages, and policies pursued by the current U.S.
Some of our product candidates have produced results only in nonclinical settings, or for other indications than those for which we contemplate conducting development and seeking FDA or other regulatory approval, and we cannot give any assurance that we will generate data for any of our product candidates sufficiently supportive to receive regulatory approval in our planned indications, which will be required before they can be commercialized.
Even if we obtain regulatory approvals for any of our product candidates, our products will be subject to ongoing regulatory oversight.
+7 more — sign up free →
REMOVED
As of February 20, 2025, there were 81,484,950 shares of the registrant s common stock outstanding.
Regulatory approval processes are lengthy, time-consuming and inherently unpredictable.
Some of our product candidates have produced results only in nonclinical settings, or for other indications than those for which we contemplate conducting development and seeking U.S.
Food and Drug Administration ( FDA ) or other regulatory approval, and we cannot give any assurance that we will generate data for any of our product candidates sufficiently supportive to receive regulatory approval in our planned indications, which will be required before they can be commercialized.
We target disease areas where marketed therapies often leave room for improvements in efficacy, safety, and/or dosing convenience.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →